A Roadmap for Long-Acting Therapeutics in Maternal Health
A comprehensive review in Clinical Pharmacology & Therapeutics addresses the critical need for long-acting drug delivery systems in maternal health, particularly in underserved populations. The article synthesizes insights from a recent expert workshop, highlighting persistent data gaps due to the historical exclusion of pregnant and lactating women from clinical trials. It examines the efficacy and safety considerations derived from existing long-acting antiretrovirals and explores emerging technologies, including long-acting injectable antipsychotics and reversible contraceptives. The review also discusses the role of in silico modeling and regulatory initiatives aimed at bridging these research disparities, concluding with actionable recommendations for advancing this specialized area of pharmacotherapy.
Why it might matter to you: This review directly intersects with core pharmacology concepts like therapeutic drug monitoring, pharmacokinetics, and the development of novel drug delivery systems. For professionals focused on clinical trials and personalized medicine, it outlines a strategic framework for designing safer, more effective long-acting formulations for a vulnerable, high-priority population. The discussion on in silico modeling offers a methodological advance for predicting drug behavior, which could streamline the development pipeline for new biopharmaceuticals and small-molecule drugs.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
